Background Lymphatic malformation (LM) is a form of congenital vascular malformation with a low incidence. Although LM has been studied, no consensus has emerged regarding its cause or treatment. Methods In this study, we retrospectively evaluated 40 patients who visited our vascular anomalies center for the treatment of cervicofacial LM, which is a common manifestation of LM. The medical records of patients over a period of 12 years were reviewed and analyzed for commonalities regarding the diagnosis and the results of treatment. Results Suspected cervicofacial LM was confirmed through imaging studies. No difference in incidence was observed according to sex, and 73% of patients first presented with symptoms before the age of two years. The left side and the V2-V3 area were most commonly affected. No significant differences in incidence were observed among the macrocystic, microcystic, and combined types of LM. A total of 28 out of 36 patients received sclerotherapy as the first choice of treatment, regardless of the type of lesion. Complete resolution was achieved in only 25% of patients. Conclusions LM is important to confirm the diagnosis early and to choose an appropriate treatment strategy according to the stage of the disease and each individual patient's symp toms. When treatment is delayed or an incorrect treatment is administered, patient discomfort increases as the lesion gradually spreads. Therefore, more so than is the case for most other diseases, a team approach on a casebycase basis is important for the accurate and appropriate treatment of LM.
INTRODUCTION
Lymphatic malformation (LM) is a form of congenital vascular malformation that stems from the malformation of the lymphat ic vessels in soft tissues, including the skin [1] . Since the nine teenth century, LM has been known as cystic hygroma and lym phangioma, and classified as a tumor of lymphatic origin. Mul liken and Glowacki [2] coined the currently preferred term, lymphatic malformation, in their 1982 classification of vascular anomalies. LM has a slow flow and low incidence, and its causes have not been clearly delineated. van der Putte and van Limborgh [3] Cervicofacial have argued that the lymphatic system originates and develops from the venous system at six weeks of gestation; at nine to ten weeks gestation, the lymphatic system of the entire body starts to grow and form connections throughout the body. Consider able support exists for the theory that LM occurs when seques tered lymphatic tissue fails to communicate with the lymphatic and venous systems after budding during the developmental process of the normal lymphatic system [1, 4] .
Possibly due to embryological factors, LM occurs more com monly together with other vascular malformations, such as cap illary malformation and venous malformation, than it does alone, which makes it difficult to establish the precise incidence of LM. However, some authors have argued that its incidence is approx imately 2.8-5 out of 100,000 people [5, 6] . Moreover, symptoms of LM are observed immediately after birth in more than 50% of patients and are observed before the age of two years in 90% of patients [7] .
Histologically, LM is classified into the macrocystic type, con sisting of cysts larger than 2 cm with clear boundaries (previous ly known as cystic hygromas), and the microcystic type, consist ing of cysts smaller than 2 cm that appear diffuse and sprouted without clear boundaries (previously known as lymphangio ma). The two types coexist in the combined type [2, 8, 9] . LM can occur anywhere in the lymphatic system, but previous research has indicated that up to 75% of cases of LM manifest as cervicofacial lesions (in the tongue, lip, cheek, or neck), as these are regions where the lymphatic system predominates [8, 10, 11] . The macrocystic type has been most frequently reported to ap pear in the neck area, while the microcystic type has been report ed to appear most frequently in the intraoral cavity and cheek area.
Unlike LM in other regions, cervicofacial LM can cause airway obstruction and become lifethreatening. Since cosmetic sequel ae and functional impairment are possible complications of the surgical treatment of LM, it is important to administer early treat ment after an accurate diagnosis and to choose appropriate meth ods according to the location and depth of the lesion.
The objective of the present study was to analyze the clinical features, diagnostic process, treatment methods, and treatment results for patients with cervicofacial LM.
METHODS
This study included 40 patients who were collaboratively diag nosed with cervicofacial LM by specialists from the fields of plastic surgery, dermatology, radiology, and vascular surgery. We then retrospectively reviewed the patients' medical histories. We excluded cases accompanied by primary lymphedema, other types of vascular anomalies, or congenital cysts, such as branchi al cleft cysts or thyroglossal duct cysts.
Based on each patient's medical history, we determined the age at the first presentation of symptoms, the age at the patient's first visit to the treatment center, sex, and average followup pe riod. The distribution of LM was classified into the left, center, or right side of the head and neck, and into the V1, V2, and V3 areas. The location of LM was classified into 10 regions, includ ing the scalp and forehead, ear, cheek, and intraoral locations. When LM was present in more than two regions, we obtained the number of cysts in each location. Moreover, LM was classi fied as macrocystic, microcystic, or a combined type in which both types coexisted, using a cutoff value of 2 cm for distingui shing between the macrocystic and microcystic types [2, 12] . A team of specialists conducted a physical examination in all patients with suspected vascular malformations. Magnetic reso nance imaging (MRI) [13, 14] and Doppler ultrasonography (DUSG) [15, 16] were used to confirm the diagnosis of patients with suspected LM. The treatment team gathered and discussed the type and location of LM, as well as cosmetic factors, in order to decide on a course of treatment. Sclerotherapy, surgical resec tion, and CO2 laser ablation using OK432 and bleomycin were the primary courses of initial treatment, and depending on the situation, more than two types of treatment methods were used sequentially. DUSG and the presence of residual symptoms, which can be grossly confirmed through a physical examination, were used to evaluate the extent to which the LM lesions de creased in size and to classify the therapeutic effect as aggravat ed, partially improved ( < 25%), improved ( > 50%), or com pletely improved ( > 90%).
RESULTS

Clinical features
A total of 1,752 patients who visited our treatment center over a period of 12 years were diagnosed with vascular malformations. Of these patients, 149 (8.5%) had pure LM, excluding mixed types of vascular malformations, such as lymphaticovenous mal formation. Forty patients (2.3%) had a cervicofacial lesion. The study participants included 21 males and 19 females-an approx imately 1:1 ratio-and no significant difference in incidence was observed with respect to sex. The average age at the first presentation of symptoms in the patients was 4.47 ± 8.82 years old (range, 0 month-30 years) for males and 5.26 ± 10.43 years old (range, 0 month-46 years) for females. A total of 21 patients (53%) showed symptoms at birth, including 10 males (48%) and 11 females (58%). A total of eight patients (four males, four females) showed symptoms after birth but before the age of two years. The average followup period was 61.2 ± 79.25 months (range, 1-325 months), including four patients who were lost to followup.
Type, distribution, and location
Based on the initial physical examination and imaging studies of patients with suspected cervicofacial vascular anomalies, we evaluated the type of LM present in each patient as well as its distribution and location. Thirteen patients had macrocystic
Types of cervicofacial lymphatic malformations, with no significant differences observed according to type.
Fig. 1. Type of cervicofacial lymphatic malformation
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The areas with the most lesions were the cheek (19 patients), mandible (13 patients), and neck (10 patients). LM (32.5%), 14 patients had microcystic LM (35%), and 13 patients had combined LM, and these differences were not sta tistically significant (Fig. 1) . Fourteen patients (35%) had rightside lesions, 21 patients (53%) had leftside lesions, and five patients (12%) had center lesions. Six patients (15%) had V1 lesions, 11 patients (28%) had V2 lesions, and 12 patients (30%) had V3 lesions. Among the patients with LM in more than two areas, nine (23%) had V2-V3 lesions and two (5%) had V1-V3 lesions (Fig. 2) . No significant differences were observed in the distribution of le sions according to the type of LM. We then categorized the lesions depending on whether they occurred in the scalp and forehead, eyelid, orbital cavity, ear, cheek (parotid area), nose, lip, mandible, neck, or intraoral area. The highest frequency was observed in the cheek (parotid area) (19 patients, 47.5%), mandible (13 patients, 32.5%), and neck (10 patients, 25%). Fifteen patients (37.5%) showed a widespread distribution, with LM present in at least two regions. The mac rocystic type was commonly found in the neck area and the mi crocystic type was commonly found in the cheek (parotid area) and lip. The combined type, however, showed an even distribu tion over the cervicofacial region (Fig. 3) .
Diagnosis
After taking a medical history from patients with suspected vas cular anomalies and conducting a physical examination, LM was confirmed using imaging studies such as DUSG, which is noninvasive and relatively accessible, or MRI, which allows sub types to be identified and the extent of the lesion and of inva sion into nearby soft tissues to be determined. Thirtythree pa tients (82.5%) underwent DUSG and 36 patients (90%) un derwent MRI. Due to the burden of radiation, computed to mography was only performed when the size of the lesion and its relationships with adjacent structures needed to be clarified, and was administered to only 15 patients (37.5%). The diagno sis was confirmed by biopsy in 13 patients, including those who underwent surgical resection during the treatment process.
Treatment
The treatment strategies used included sclerotherapy, surgical excision, and simple passive observation, and the treatment methods included CO2 laser ablation, OK432, or bleomycin.
Of the 40 patients diagnosed with cervicofacial LM, four were lost to followup and two showed complete improvement after six months of followup.
Of the 12 patients with macrocystic LM, four (33%) received sclerotherapy more than once, and three of the 13 patients with microcystic LM (23%) received sclerotherapy more than once as well as surgical excision. Of the 11 patients with combined type LM, three (27%) received sclerotherapy once and four (36%) received sclerotherapy more than once. Of the 36 pa tients who were diagnosed with LM and were followed up at our treatment center, a total of 28 (78%) received sclerotherapy at least once, regardless of the type of LM.
Improvement or complete improvement was observed in eight of the 12 patients (67%) with macrocystic LM, nine of the 13 patients (69%) with microcystic LM, and seven of the 11 pati ents (63%) with combinedtype LM. Similar trends in improve ment were noted in all three types of LM. However, aggravation despite continuous treatment was observed in one patient (8%) with macrocystic LM, one patient (7%) with microcystic LM, and four patients (36%) with combinedtype LM, showing a clear difference among the three conditions. Since combined type LM was associated with a higher likelihood of aggravation despite continuous treatment, including surgical resection and sclerotherapy, many patients experienced difficulty after treat ment (Table 1) . tial diagnosis, a medical history was taken and the physical ex amination took place during a team conference. After an imag ing study using DUSG and MRI, the child was diagnosed with combinedtype LM (Fig. 4A-C) . In order to treat and prevent infection, bleeding, and ulceration, the patient underwent CO2 laser ablation and showed improvement. The patient also expe rienced swelling, aggravation, and pain in his forehead and eye lid. Sclerotherapy using bleomycin was administered, which al leviated the symptoms, and the patient underwent continual followup after the initial diagnosis. Two years later, the child again experienced swelling, aggravation, and pain in the areas of the previous forehead lesion and the eyelid, and underwent a second round of sclerotherapy using bleomycin (Fig. 4D-F) . Appropriate treatment methods were chosen to address chang es in the patient's condition according to the consensus of our center's vascular anomalies team.
Case 2
A child presented with swelling on the left cheek area at birth and visited our institution for a palpable mass observed in the same area six months after birth, as well as for increased mass size and swelling, facial asymmetry, and aggravation. After the medical history and physical examination were completed, the medical team diagnosed the patient with combinedtype LM after completing an imaging study with MRI and DUSG ( Fig.  5A-C) . The child underwent surgical resection to remove the macrocystic mass and the symptoms improved. Although fol lowup observations using DUSG confirmed the removal of macrocystic LM, the microcystic LM remained and additional sclerotherapy was performed (Fig. 5D, E) . No interference with the child's daily activity was observed. Based on the findings of improvement in the microcystic LM lesions using DUSG, con tinuous followup was planned with the understanding that the appropriate treatment method for any changes in the condition of the patient would be chosen based on the consensus of the center's vascular anomalies team (Fig. 5F ).
Case 3
A woman presented with swelling on the right cheek area and visited our institution for a palpable mass observed in the same area, as well as for increased mass size and swelling, facial asym metry, and aggravation. After the medical history and physical examination were completed, the medical team diagnosed the patient with microcystic LM after completing an imaging study with MRI and DUSG (Fig. 6A-C) . The woman underwent sclerotherapy using bleomycin to remove the microcystic mass and her symptoms were shown to improve by DUSG. (Fig. 6D,  E) . Since her microcystic LM was found to have completely im proved, the plan was to perform continuous followup and to choose the appropriate treatment method for any changes in the condition of the patient according to the consensus of the cen ter's vascular anomalies team.
DISCUSSION
Many studies, including research by Padwa and Mulliken, have established that LM is a congenital vascular malformation [7,12 14,17] .
In agreement with the extant literature, we found that 52.5% of cases (21 patients) presented with symptoms at birth, and that patients who presented with symptoms before the age of two years accounted for 72.5% of cases (29 patients). In patients who presented with symptoms after the age of two years, LM was located in deep soft tissue lesions, and the symptoms were initially not observable with the naked eye. However, as the size of the lesion increased or the lesion sprouted diffusely due to an event such as trauma or infection, symptoms began to arise and patients visited the hospital. We observed a 1:1 sex ratio, which is consistent with the results of previous studies that have dem onstrated no relationship between the incidence of LM and sex [2, 8, 9, 14] .
As mentioned above, considerable support exists for the theo ry that LM occurs during the formation of the venous and lym phatic system at six to ten weeks of gestation, when sequestered lymphatic tissue fails to communicate with the lymphatic and venous system [1, 4] . Therefore, LM generally manifests as cer vicofacial lesions in areas where the lymphatic system first forms, most notably in the parotid area (cheek), mandible, and neck area, which account for a large part of the lymphatic system [8, 11, 17, 18] . The results of our study also indicated that 80% of cases (32 patients) occurred in the V2-V3 region, which includes the cheek, intraoral area, mandible, and neck (Fig. 3) .
The clinical features found in this study were similar to those reported by previous research. However, Greene [19] and Bis dorff et al. [20] reported that LM on the left side occurred in 62% to 70% of cases, while other authors have argued that LM has an equal incidence on the left and right side, and still other studies have reported opposing views regarding leftright dis parities in the affected site. In the present study, 52.5% of cases (21 patients) had LM on the left side, compared to 35% of cases (14 patients) that were diagnosed with LM on the right side (Fig. 2) . Studies of large patient groups have not been conduct ed to date, and thus few theories have been proposed regarding the cause of LM. The lymphatic system itself predominates on the left side, which we believe may be a possible reason for our findings [20, 21] . An accurate medical history and physical examination are im portant for diagnosing patients with vascular anomalies. Accord ingly, in our vascular anomalies center, history taking and physi cal examinations are performed collaboratively at a weekly con ference by a team of specialists from each related department. Imaging studies are then designed to focus on the suspected di agnosis. Based on the characteristics of the lesions in the cervi cofacial region, which has ample soft tissue and contains many important organs, the size and form of LM can be confirmed. However, DUSG, which is often the first choice for diagnosing vascular anomalies, is often ineffective for identifying LM in deep soft tissue. Therefore, computed tomography must be per formed selectively, taking into account the average age of the pa tients and their vulnerability to radiation. Consequently, MRI is the firstchoice imaging modality for LM at our institution. In our study, 36 patients (90%) underwent MRI. Taking into ac count the cost benefits and ease of accessibility during pregnan cy, 33 patients (82.5%) received additional testing using DUSG. Furthermore, DUSG was the modality most commonly used to observe the therapeutic effect of treatment during followup. Similarly to the present study, other authors have adopted the strategy of first obtaining a medical history and conducting a physical examination, then designing a treatment strategy after using MRI and DUSG to confirm the diagnosis and classifica tion of LM [1, 13, 2224] .
Cervicofacial LM, as indicated by many studies, is a form of vascular malformation that is difficult to eradicate. Various sug gestions for treatment methods have been made, including laser ablation, surgical resection, and sclerotherapy, depending on the type and location of LM [8, 9, 18, 25] . Of the 36 patients in our study who received treatment, 18 patients (50%) received sclero therapy only. Surgical resection can be performed only when LM is located in an accessible area, meaning that only eight pa tients (22%) underwent surgical resection with sclerotherapy. Sclerotherapy was used as first choice of treatment regardless of the type of LM. Surgical resection was employed primarily for macrocystic LM, which forms cysts with clear boundaries, meaning that surgical resection poses no risk of damage to the neighboring structures. It was also used to a limited extent as a method for reducing the range of cosmetic side effects after treatment in some cases of microcystic and combinedtype LM.
Of the 36 patients, excluding four patients who were lost to fol lowup, nine (25%) showed complete improvement, 15 (42%) showed improvement, six (17%) showed partial improvement, and six (17%) showed aggravation. Taking into account the high risk of recurrence of LM and the difficulty of eradication, these therapeutic outcomes may be interpreted as positive.
The diagnosis, examination, and choice of a treatment method are important factors in the treatment of various types of vascu lar anomalies, and this is even more imperative for types of vas cular anomalies with no established standard protocol. Since a general diagnosis and treatment protocol has not been establish ed for LM, a multifaceted approach is required for each case. Based on 12 years of experience, we argue that the proper treat ment method should involve a team of specialists from plastic surgery, pediatrics, dermatology, radiology, and vascular surgery, and that treatment should be planned on a casebycase basis in stead of following a standardized protocol.
